Evidence map›Paper›PMID 16891672›Full record

ReviewImmunologic research2006

Chemoattractant receptor signaling and the control of lymphocyte migration.

John H Kehrl

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Unrestrained GαFrontiers in immunology · 2021
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. RGS16 attenuates pulmonary Th2/Th17 inflammatory responses.Journal of immunology (Baltimore, Md. : 1950) · 2012
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

John H KehrlB Cell Molecular Immunology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. jkehrl@niaid.nih.gov
National Institute of Allergy and Infectious Diseases · US

Funding

Control Of G Protein Signaling: Role Of The RGSsZIAAI000738 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KEHRL, JOHN H · 2009 to 2025
$15.9M
CONTROL OF G PROTEIN SIGNALING: ROLE OF THE RGSSZ01AI000738 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI KEHRL, JOHN H · 1996 to 2008
$3.9M
6 · The paper itself

Abstract

This review focuses on mechanisms by which chemoattractant receptors activate downstream signaling pathways in lymphocytes. An emphasis is placed on heterotrimeric G protein signaling with a discussion of the specific heterotrimeric G-proteins involved in lymphocyte chemotaxis and motility and the role of regulator of G protein signaling (RGS) proteins in controlling the activation of downstream effectors. Also considered are those direct downstream effectors known to function in lymphocyte chemotaxis and/or motility. The consequences of targeting genes suspected, known, or serendipitously found to be involved in chemokine receptor signaling pathways form much of a basis for the review. When needed for clarification, reference to studies of chemoattractant signaling in model organisms and in neutrophils will be compared and contrasted to studies in lymphocytes. Finally, the emergence of tools to image lymphocyte in vitro and in vivo will be mentioned as they are increasing helpful for the analysis of lymphocyte trafficking and amendable to the study of chemokine receptor signaling.

Indexed as

AnimalsCell MovementGTP-Binding ProteinsHumansLymphocytesModels, MolecularReceptors, Formyl PeptideSignal TransductionGTP-Binding ProteinsReceptors, Formyl Peptide

Identifiers

PMID16891672
OpenAlexW2039391077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.